Merck (MRK) EPS (Basic) Growth (1y) (2010 - 2026)
Powered by 
Analysis
Merck (MRK) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.71 Bn | 622.96 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 447.56 Bn | 440.99 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 359.50 Bn | 352.36 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 270.28 Bn | 262.59 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 157.12 Bn | 145.42 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.51 Bn | 45.13 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.52 Bn | 43.52 Bn | - | - |
| 8 | Incyte | 25.21 Bn | 20.67 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.35 Bn | 18.69 Bn | 683.80 Mn | 13.91% |
| 10 | Neurocrine Biosciences | 16.02 Bn | 15.63 Bn | 935.80 Mn | 31.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -130.68% |
| Mar 31, 2026 | -185.16% |
| Dec 31, 2025 | -19.94% |
| Sep 30, 2025 | 85.94% |
| Jun 30, 2025 | -18.14% |
| Mar 31, 2025 | 7.09% |
| Dec 31, 2024 | 405.99% |
| Sep 30, 2024 | -33.37% |
| Jun 30, 2024 | 191.62% |
| Mar 31, 2024 | 69.08% |
| Dec 31, 2023 | -140.54% |
| Sep 30, 2023 | 45.79% |
| Jun 30, 2023 | -250.75% |
| Mar 31, 2023 | -34.67% |
| Dec 31, 2022 | -19.84% |
| Sep 30, 2022 | -28.92% |
| Jun 30, 2022 | 155.64% |
| Mar 31, 2022 | 35.35% |
| Dec 31, 2021 | 279.91% |
| Sep 30, 2021 | 55.15% |